Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe.

Barnabas GD, Bhat TA, Goebeler V, Leclair P, Azzam N, Melong N, Anderson C, Gom A, An S, Ergin EK, Shen Y, Conrrero A, Mungall AJ, Mungall KL, Maxwell CA, Reid GSD, Hirst M, Jones S, Chan JA, Senger DL, Berman JN, Parker SJ, Bush JW, Strahlendorf C, Deyell RJ, Lim CJ, Lange PF

Open source

DOI: 10.1038/s44321-025-00212-8
Published: 2025 Apr
Container: EMBO molecular medicine
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s44321-025-00212-8,
  title = {Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe.},
  author = {Barnabas GD and Bhat TA and Goebeler V and Leclair P and Azzam N and Melong N and Anderson C and Gom A and An S and Ergin EK and Shen Y and Conrrero A and Mungall AJ and Mungall KL and Maxwell CA and Reid GSD and Hirst M and Jones S and Chan JA and Senger DL and Berman JN and Parker SJ and Bush JW and Strahlendorf C and Deyell RJ and Lim CJ and Lange PF},
  year = {2025},
  journal = {EMBO molecular medicine},
  doi = {10.1038/s44321-025-00212-8},
  url = {https://doi.org/10.1038/s44321-025-00212-8}
}

RIS

TY  - JOUR
TI  - Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe.
AU  - Barnabas GD
AU  - Bhat TA
AU  - Goebeler V
AU  - Leclair P
AU  - Azzam N
AU  - Melong N
AU  - Anderson C
AU  - Gom A
AU  - An S
AU  - Ergin EK
AU  - Shen Y
AU  - Conrrero A
AU  - Mungall AJ
AU  - Mungall KL
AU  - Maxwell CA
AU  - Reid GSD
AU  - Hirst M
AU  - Jones S
AU  - Chan JA
AU  - Senger DL
AU  - Berman JN
AU  - Parker SJ
AU  - Bush JW
AU  - Strahlendorf C
AU  - Deyell RJ
AU  - Lim CJ
AU  - Lange PF
PY  - 2025
JO  - EMBO molecular medicine
DO  - 10.1038/s44321-025-00212-8
UR  - https://doi.org/10.1038/s44321-025-00212-8
ER  -

APA

GD, B., TA, B., V, G., P, L., N, A., N, M., C, A., A, G., S, A., EK, E., Y, S., A, C., AJ, M., KL, M., CA, M., GSD, R., M, H., S, J., JA, C., DL, S., JN, B., SJ, P., JW, B., C, S., RJ, D., CJ, L., & PF, L. (2025). Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe.. EMBO molecular medicine. https://doi.org/10.1038/s44321-025-00212-8

Source records

pubmed · retrieved 2026-09-26T18:04:31.273Z
europe-pmc · retrieved 2026-09-26T18:04:31.276Z
doaj · retrieved 2026-09-26T18:04:31.268Z